You are here: Industry Insights > European Commission

News List

Dilemma over AI and drug patenting already under debate nature
August 17, 2018
Initiatives are already under way to avoid ill-considered moves concerning the impact of artificial intelligence (AI) on drug patenting (see L. Heuer Nature 558, 519; 2018).
Clovis Oncology Announces European Commission Authorization of Rubraca (rucaparib) for Women with Recurrent Ovarian Cancer firstwordpharma
May 30, 2018
today announced that the European Commission (EC) has authorized Rubraca (rucaparib) as monotherapy treatment of adult patients with platinum-sensitive, relapsed or progressive
European Commission grants orphan drug status to Apogenix’s asunercept for MDS pharmaceufical-technology
October 10, 2017
MDS is a disorder of the bone marrow characterised by ineffective haematopoiesis (blood cell formation) and can cause severe anaemia.
European Commission approves Janssen’s Symtuza for HIV-1 treatment pharmaceufical-technology
September 28, 2017
The European Commission (EC) has approved Janssen-Cilag International’s Symtuza for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
European Commission approves Roche’s tocilizumab to treat giant cell arteritis pharmaceufical-technology
September 26, 2017
Roche’s Actemra / RoActemra (tocilizumab) has received approval from the European Commission (EC) to treat giant cell arteritis (GCA).
European Commission Approves Bavencio americanpharmaceuticacreview
September 22, 2017
BAVENCIO is expected to become commercially available to patients in Europe by prescription within the coming months, with initial launches in Germany and UK expected as early as October 2017.
European Commission licences EUSA’s advanced RCC treatment fotivda pharmaceufical-technology
September 01, 2017
Jazz Pharmaceuticals subsidiary EUSA Pharma’s fotivda (tivozanib) has been licensed by the European Commission (EC) for first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
European Commission Grants Approval for Mavenclad americanpharmaceuticalreview
August 28, 2017
Merck announced the European Commission (EC) has granted marketing authorization for MAVENCLAD 10mg (Cladribine Tablets) for the treatment of highly active relapsing multiple sclerosis (RMS) in the 28 countries of the European Union (EU) in addition to No
European Commission approves Novartis's Zykadia for ALK-positive NSCLC patients pharmaceutical-technology
July 04, 2017
The European Commission (EC) has given approval for the expansion of use for Swiss healthcare company Novartis's Zykadia (ceritinib) drug for treatment of advanced non-small cell lung cancer (NSCLC) in the EU.
European Commission approves Roche’s new Esbriet tablet formulation for IPF pharmaceutical-technology
July 03, 2017
The European Commission (EC) has approved a new tablet formulation of Swiss pharmaceutical company Roche’s Esbriet (pirfenidone) to treat patients with mild to moderate idiopathic pulmonary fibrosis (IPF).

Previous page 1 2 3 Next page